Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted.

Panda, Aditya K; Padhi, Sunali; Pati, Abhijit; Nayak, Tapan Kumar Singh

Panda, Aditya K; Padhi, Sunali; Pati, Abhijit; Nayak, Tapan Kumar Singh.

Panda AK; Department of Bioscience and Bioinformatics, Khallikote University, Berhampur, Odisha, 761008, India. adityarmrc@gmail.com.
Padhi S; Department of Bioscience and Bioinformatics, Khallikote University, Berhampur, Odisha, 761008, India.
Pati A; Department of Bioscience and Bioinformatics, Khallikote University, Berhampur, Odisha, 761008, India.
Nayak TKS; Department of Bioscience and Bioinformatics, Khallikote University, Berhampur, Odisha, 761008, India.

Hum Cell ; 34(6): 1943-1944, 2021 Nov.

Article in English | MEDLINE | ID: covidwho-1409379

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Antibodies, Monoclonal/therapeutic use; COVID-19 Drug Treatment; Receptors, Interleukin-6/antagonists & inhibitors; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal, Humanized/pharmacology; Female; Humans; Male; Meta-Analysis as Topic; Randomized Controlled Trials as Topic

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Receptors, Interleukin-6 / Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment / Antibodies, Monoclonal Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Limits: Female / Humans / Male Language: English Journal: Hum Cell Year: 2021 Document Type: Article Affiliation country: S13577-021-00616-x

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google